Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion
- 4 July 2008
- journal article
- review article
- Published by Wiley in Diabetic Medicine
- Vol. 25 (7), 765-774
- https://doi.org/10.1111/j.1464-5491.2008.02486.x
Abstract
Aims Continuous subcutaneous insulin infusion (CSII) is a recommended treatment for reducing severe hypoglycaemia in Type 1 diabetes, but the change in hypoglycaemia compared with multiple daily insulin injections (MDI) is unclear. We therefore conducted a meta-analysis comparing severe hypoglycaemia and glycaemic control during CSII and MDI. Methods Databases and literature (1996-2006) were searched for randomized controlled trials (RCTs) and before/after studies of >= 6 months' duration CSII and with severe hypoglycaemia frequency > 10 episodes/100 patient years on MDI. Results In 22 studies (21 reports), severe hypoglycaemia during MDI was related to diabetes duration (P = 0.038) and was greater in adults than children (100 vs. 36 events/100 patient years, P = 0.036). Severe hypoglycaemia was reduced during CSII compared with MDI, with a rate ratio of 2.89 (95% CI 1.45 to 5.76) for RCTs and 4.34 (2.87 to 6.56) for before/after studies [rate ratio 4.19 (2.86 to 6.13) for all studies]. The reduction was greatest in those with the highest initial severe hypoglycaemia rates on MDI (P < 0.001). The mean difference in glycated haemoglobin (HbA(1c)) between treatments was less for RCTs [0.21% (0.13-0.30%)] than in before/after studies [0.72% (0.55-0.90%)] but strongly related to the initial HbA(1c) on MDI (P < 0.001). Conclusions The severe hypoglycaemia rate in Type 1 diabetes was markedly less during CSII than MDI, with the greatest reduction in those with most severe hypoglycaemia on MDI and those with the longest duration of diabetes. The biggest improvement in HbA(1c) was in those with the highest HbA(1c) on MDI.Keywords
This publication has 50 references indexed in Scilit:
- Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist serviceDiabetic Medicine, 2005
- Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetesPractical Diabetes International, 2005
- An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetesDiabetes/Metabolism Research and Reviews, 2004
- Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of lifeDiabetic Medicine, 2004
- Beneficial Effects of Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Insulin Regimen Using Insulin Glargine in Type 1 DiabetesPEDIATRICS, 2004
- A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin GlargineDiabetes Care, 2004
- Continuous Subcutaneous Insulin InfusionDiabetes Care, 2004
- Insulin Pump Therapy in Patients with Type 1 Diabetes Mellitus: Results of the Nationwide Quality Circle in Germany (ASD) 1999 - 2000Experimental and Clinical Endocrinology & Diabetes, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.Diabetes Care, 1999